SuperSmart← Back to DiscoverDiscover
RESEARCH DRAFT

Research draft. Conclusions may change; review the sources and limitations before relying on them.

RESEARCH DRAFT · NOT A VERIFIED CONCLUSION

3M stopped making PFAS. Its water-settlement payments run through 2036—and historical cleanup continues.

A manufacturing exit, a drinking-water settlement and the end of environmental obligations are not the same event.

research_draftUpdated 2026-09-100 recorded actions
Conceptual generated illustration of documents and civic architectureCONCEPTUAL ILLUSTRATION

Monitor this connection

Sign in to your account to monitor updates
3Recorded evidence rows
0Investigation actions
5Review limitations
0Recorded answers

What this page shows

3M reports that it completed its PFAS manufacturing exit at the end of 2025. Yet its 2025 annual filing describes $10.5 billion to $12.5 billion in total payments for the public-water-system settlement, scheduled from 2024 through 2036. The same filing discusses separate personal-injury litigation. The manufacturing exit therefore did not close every PFAS-related issue. 3M's operations disclosure also says treatment assets at former manufacturing facilities will continue treating historical contamination and residual PFAS in waste streams. The continuing work is expressly acknowledged by the company, not evidence that the announced manufacturing exit was false. The unanswered question is which obligations will finish when: settlement payments, site-specific treatment, and unresolved claims each have their own timeline. A single headline saying a company has exited PFAS cannot answer all three.

Recorded evidence

3M / SEC filing
2025 Form 10-K: PFAS exit, public-water settlement and other litigationYear ended 2025-12-31
↗
3M
PFAS uses and applications: continuing treatment of historical manufacturing wasteAccessed 2026-09-10
↗
3M
Original public-water settlement announcement: present-value amount and payment period2023-06-22
↗

Limitations & review notes

  • Research draft. Conclusions may change; review the sources and limitations before relying on them.
  • The payment range is total scheduled settlement consideration, not the balance still unpaid as of this page's date.
  • Settlement coverage is limited; personal-injury allegations discussed in the filing are not findings of liability.
  • Manufacturing exit does not mean all product use, remediation or legacy exposure ended. This page does not infer ongoing manufacture.
  • The sources are multiple company documents, not independent source organizations.

Questions this connection opens

  1. What PFAS-related payments, treatment obligations and litigation has 3M disclosed since its manufacturing exit?
  2. Which former 3M manufacturing sites still have documented treatment obligations, and what milestones would end them?
Go deeper

Ask a follow-up question, compare another company, or review the supporting evidence.

Ask a follow-up